Vigeo debuts to reprogram tumor microenvironment

Vigeo emerged from stealth Friday with $27.5 million from Morningside Venture Capital and a cancer candidate already in the clinic.

Vigeo Therapeutics Inc. (Cambridge, Mass.) is developing a pipeline of peptides, fusion proteins and antibodies that target genetically normal cells within the tumor microenvironment and reprogram them to be immune-stimulating and tumor-inhibiting. As normal cells are less likely to develop mutation-based resistance, the biotech believes its approach can be effective in cancers where other therapies have failed, and have fewer side effects...